SEC Form SC 13G filed by EDAP TMS S.A.
$EDAP
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | Overweight → Neutral | Piper Sandler | |
| 4/4/2025 | $2.00 | Buy → Hold | Jefferies |
| 11/1/2022 | $11.00 | Buy | Jefferies |
| 11/19/2021 | $12.00 → $11.00 | Buy | HC Wainwright & Co. |
4 - EDAP TMS SA (0001041934) (Issuer)
4 - EDAP TMS SA (0001041934) (Issuer)
4 - EDAP TMS SA (0001041934) (Issuer)
Piper Sandler downgraded EDAP TMS SA from Overweight to Neutral
Jefferies downgraded EDAP TMS SA from Buy to Hold and set a new price target of $2.00
Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00
, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial ResultsInvestor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announce
, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4th, 2026 AUSTIN, Texas, May 21th, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Jefferies 2026 Global Healthcare Conference in New York. Date: Thursday, June 4th Time: 2:00-2:30 PM ET Format: Presentation and 1x1 investor meetings Webcast: https://event.summitcast.com
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ:EDAP, "EDAP")) and Profound Medical Corp. (NASDAQ:PROF, TSX:PRN, "Profound")
8-K - EDAP TMS SA (0001041934) (Filer)
8-K - EDAP TMS SA (0001041934) (Filer)
DEFA14A - EDAP TMS SA (0001041934) (Filer)
4 - EDAP TMS SA (0001041934) (Issuer)
, May 07, 2026 (GLOBE NEWSWIRE) -- EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth 78% Growth in First Quarter HIFU Revenue Year-Over-Year53% Growth in First Quarter U.S. HIFU Procedures Year-Over-Year83% Growth in First Quarter Focal One Shipments Year-Over-Year Demonstrating Strong MomentumLandmark HIFI-2 Study Results Further Strengthen Focal One Robotic HIFU Market Position AUSTIN, Texas, May 7, 2026 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today reported financial results for the first quarter of 2026. "We delivered our strongest HIFU quarter t
, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas, April 16, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2026, before market open on Thursday, May 7, 2026. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for c
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One Procedures69% Full-Year YoY Growth in Focal One System Placements28% Q4 YoY Growth in U.S. Procedures, Marking the Second Consecutive Quarter of Double-Digit Procedure GrowthDemand for Focal One Systems Remains Strong with System Placements in Academic Cancer Centers, Community Hospitals, and Large Integrated Healthcare Networks Company Reiterates its Previously Issued 2026 Revenue Guidance; HIFU Revenue Expected to Grow Between 34% and 45% YoY AUSTIN, Texas, March 25, 2026 - E
, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial ResultsInvestor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announce
, May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026 AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at 8:00 am ET on Monday, June 1, 2026. The presentation will be led by members of the Company's Executive Leadership Team and will include remarks from a prominent urologic surgeon and expert in focal therapy and Focal One HIFU. The event will also cover an overview of the Company's business plans and strategic path forward, including our: Growth Strategy and Long-Term Financial TargetsExpanding Th
EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (NASDAQ:EDAP) ("the Company" or "EDAP"), a global leader in therapeutic ultrasound technology, today announced the appointment of David Horn to its Board of Directors, effective February 11, 2026. The addition of Mr. Horn strengthens the Board with extensive experience both advising and leading companies through periods of strategic growth and transformation. Mr. Horn will serve as a member of the Company's Audit Committee and Nominations Committee. "We are pleased to welcome David to the EDAP Board," said Lance Willsey, Chairman of the Board of EDAP. "David brings dee
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)